

49288-0693-3
TREATMENT SET TS329905
National Drug Code Directory

The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. § 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily.

49288-0693-3 Treatment Set Ts329905

<i>Labeler Name</i>	Antigen Laboratories, Inc.	Name of Company corresponding to the labeler code segment of the ProductNDC.
<i>NDC Package Code</i>	49288-0693-3	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
<i>Proprietary Name</i>	Treatment Set Ts329905	Also known as the trade name. It is the name of the product chosen by the labeler.
<i>11 Digit NDC Code</i>	49288-0693-03	It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format.
<i>Product NDC</i>	49288-0693	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
<i>Product Type Name</i>	HUMAN PRESCRIPTION DRUG	Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the "Document Type" of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
<i>Non Proprietary Name</i>	Treatment Set Ts329905	Sometimes called the generic name, this is usually the active ingredient(s) of the product.
<i>Package Description</i>	10 mL in 1 VIAL, MULTI-DOSE (49288-0693-3)	A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE.
<i>Marketing Category Name</i>	BLA	Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
<i>Application Number</i>	BLA102223	This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. "part 341"). For unapproved drugs, this field will be null.

<i>Product Marketing Start Date</i>	19861031	This is the date that the labeler indicates was the start of its marketing of the drug product.
<i>Dosage Form Name</i>	INJECTION, SOLUTION	The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
<i>Route Name</i>	INTRADERMAL; SUBCUTANEOUS	The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
<i>Substance Name</i>	CYNODON DACTYLON POLLEN; RUMEX ACETOSELLA POLLEN; AMARANTHUS RETROFLEXUS POLLEN; KOCHIA SCOPARIA POLLEN; IVA ANNUA VAR. ANNUA POLLEN; AMBROSIA TRIFIDA POLLEN; AMBROSIA ARTEMISIIFOLIA POLLEN; AMBROSIA PSILOSTACHYA POLLEN; SALSOLA KALI POLLEN; PLANTAGO LANCEOLATA POLLEN; CARYA ALBA POLLEN; CARYA ILLINOINENSIS POLLEN; JUNIPERUS VIRGINIANA POLLEN; ACER NEGUNDO POLLEN; FRAXINUS AMERICANA POLLEN; ULMUS AMERICANA POLLEN; QUERCUS ALBA POLLEN; POPULUS DELTOIDES POLLEN; BETULA NIGRA POLLEN; POA PRATENSIS POLLEN; SORGHUM HALEPENSE POLLEN; CHENOPODIUM ALBUM POLLEN	This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
<i>Strength Number</i>	66.67; .0017; .0017; .0017; .0017; .00056; .00056; .00056; .0017; .0017; .00083; .00083; .0017; .0017; .0017; .0017; .0017; .0003; .0003; 666.67; .0003; .0017	These are the strength values (to be used with units below) of each active ingredient, listed in the same order as the SubstanceName field above.
<i>Strength Unit</i>	[BAU]/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL; [BAU]/mL; g/mL; g/mL	These are the units to be used with the strength values above, listed in the same order as the SubstanceName and SubstanceNumber.

<i>Pharmaceutical Classes</i>	Increased Histamine Release [PE], Cell-mediated Immunity [PE], Increased IgG Production [PE], Pollen [CS], Allergens [CS], Standardized Pollen Allergenic Extract [EPC], Non-Standardized Pollen Allergenic Extract [EPC], Cell-mediated Immunity [PE], Increased IgG Production [PE], Pollen [CS], Increased Histamine Release [PE], Allergens [CS], Non-Standardized Pollen Allergenic Extract [EPC], Increased Histamine Release [PE], Cell-mediated Immunity [PE], Pollen [CS], Allergens [CS], Non-Standardized Pollen Allergenic Extract [EPC], Increased Histamine Release [PE], Cell-mediated Immunity [PE], Increased IgG Production [PE], Pollen [CS], Allergens [CS], Non-Standardized Pollen Allergenic Extract [EPC], Increased Histamine Release [PE], Cell-mediated Immunity [PE], Increased IgG Production [PE], Pollen [CS], Allergens [CS], Non-Standardized Pollen Allergenic Extract [EPC], Increased Histamine Release [PE], Cell-mediated Immunity [PE], Pollen [CS], Allergens [CS], Standardized Pollen Allergenic Extract [EPC], Increased Histamine Release [PE], Cell-mediated Immunity [PE], Increased IgG Production [PE], Pollen [CS], Allergens [CS], Non-Standardized Pollen Allergenic Extract [EPC], Increased Histamine Release [PE], Cell-mediated Immunity [PE], Pollen [CS], Allergens [CS], Non-Standardized Pollen Allergenic Extract [EPC], Increased Histamine Release [PE], Cell-mediated Immunity [PE], Increased IgG Production [PE], Pollen	These are the reported pharmaceutical class categories corresponding to the SubstanceNames listed above.
-----------------------------------	--	---

	[CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen	
--	---	--

	[CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS]	
--	--	--

<i>Status</i>	Deprecated	Possible status values: Active
Active NDC Code Deprecated
Deprecated NDC Code Unfinished (Unapproved) The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved.
<i>Last Update Date</i>	2019-09-21	The date that a record was last updated or changed.

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance, Immediate Office
Drug Registration and Listing Team
10903 New Hampshire Ave
Silver Spring, MD 20993-0002
Email: eDRLS@fda.hhs.gov

For all questions regarding this bundle please contact Support@DataLabs.Health. Also feel free to let us know about any suggestions or concerns. All additional information as well as customer support is available at <https://www.datalabs.health/>.